Activation of the RAS pathway has been implicated in oncogenesis and developmental disorders called RASopathies. Germline mutations in BRAF have been identified in 50-75% of patients with cardio-facio-cutaneous (CFC) syndrome, which is characterized by congenital heart defects, distinctive facial features, short stature and ectodermal abnormalities. We recently demonstrated that mice expressing a Braf Q241R mutation, which corresponds to the most frequent BRAF mutation (Q257R) in CFC syndrome, on a C57BL/6J background are embryonic/neonatal lethal, with multiple congenital defects, preventing us from analyzing the phenotypic consequences after birth. Here, to further explore the pathogenesis of CFC syndrome, we backcrossed these mice onto a BALB/c or ICR/CD-1 genetic background. On a mixed (BALB/c and C57BL/6J) background, all heterozygous Braf Q241R/+ mice died between birth and 24 weeks and exhibited growth retardation, sparse and ruffled fur, liver necrosis and atrial septal defects (ASDs). In contrast, 31% of the heterozygous Braf Q241R/+ ICR mice survived over 74 weeks. The surviving Braf Q241R/+ ICR mice exhibited growth retardation, sparse and ruffled fur, a hunched appearance, craniofacial dysmorphism, long and/or dystrophic nails, extra digits and ovarian cysts. The Braf Q241R/+ ICR mice also showed learning deficits in the contextual fear-conditioning test. Echocardiography indicated the presence of pulmonary stenosis and ASDs in the Braf Q241R/+ ICR mice, which were confirmed by histological analysis. These data suggest that the heterozygous Braf Q241R/+ ICR mice show similar phenotypes as CFC syndrome after birth and will be useful for elucidating the pathogenesis and potential therapeutic strategies for RASopathies. † These authors contributed equally to this work.
Introduction
The RAS/mitogen-activated protein kinase (MAPK) pathway plays important roles in cellular proliferation, differentiation, apoptosis and senescence (1) . Germline mutations in components of the RAS/MAPK pathway cause partially overlapping developmental disorders called 'RASopathies' or 'RAS/MAPK syndromes' (2, 3) . These disorders include cardio-facio-cutaneous (CFC) syndrome, Noonan syndrome, Costello syndrome, Noonan syndrome with multiple lentigines ( previously known as LEOPARD syndrome), neurofibromatosis type 1, Legius syndrome (neurofibromatosis 1-like) and capillary malformation-arteriovenous malformation syndrome (2) (3) (4) . With the exception of Noonan syndrome with multiple lentigines that results from a loss of function PTPN11 mutation, these syndromes usually result from the activation of the RAS/MAPK pathway (2) (3) (4) .
CFC syndrome is characterized by congenital heart defects, a distinctive facial appearance, short stature, moderate to severe mental retardation, seizures and ectodermal abnormalities, such as sparse, fragile hair and hyperkeratotic skin lesions (5, 6) . The cardiac defects observed in CFC syndrome are pulmonary valve stenosis, hypertrophic cardiomyopathy, atrial septal defects (ASDs), ventricular septal defects (VSDs) and arrhythmia (5, 6) . Germline missense mutations in BRAF occur in 50-75% of CFC syndrome patients. Germline mutations in MAP2K1/2 (MEK1/2) and KRAS have been identified in ∼25% and <2% of CFC patients (7) (8) (9) , respectively. The most common BRAF mutation in human cancers is the substitution of the residue valine at position 600 with glutamic acid (p.V600E), which has not been identified in CFC syndrome (2, 10) . In contrast, the most common mutation among CFC syndrome patients with a BRAF mutation is an arginine for glutamine substitution at position 257 (p.Q257R), which increases the kinase activity of BRAF, similar to the BRAF V600E mutation (7, 8, 11) . The presence of malignant tumors is rare in CFC syndrome; three individuals with BRAF mutations have been reported to have developed acute lymphoblastic leukemia and non-Hodgkin's lymphoma (5, 12) .
We have recently described heterozygous knock-in mice expressing the Braf Q241R mutation on a C57BL/6J background (Braf Q241R/+ B6 mice); this corresponds to the BRAF Q257R mutation in humans (13) . The Braf Q241R/+ B6 mice exhibited embryonic/ neonatal lethality. The Braf Q241R/+ B6 embryos and neonates had many characteristic features of patients with CFC syndrome, including skeletal abnormalities, lymphatic defects, cardiomegaly, pulmonary valve stenosis and VSDs. Prenatal treatment with a MEK inhibitor, PD0325901, or a histone 3 demethylase inhibitor, GSK-J4 or NCDM-32b, rescued the embryonic and postnatal lethality in the Braf Q241R/+ B6 mice. Some CFC syndrome patients die of hydrops fetalis, heart failure or chylothorax in the perinatal period (14) (15) (16) , similar to the Braf Q241R/+ B6 mice. However, most CFC syndrome patients survive to adulthood, showing a distinctive facial appearance, growth retardation, intellectual disability, heart defects and skin abnormalities (9, 12, 15) . To better understand the molecular pathogenesis of individuals with CFC syndrome from the neonatal period to adulthood, we analyzed knock-in mice expressing a developmental-specific Braf Q241R mutation on a BALB/c or ICR genetic background.
Results
The Braf Q241R/+ mice on a BALB/c background exhibit growth retardation, decreased survival, fur abnormalities, liver necrosis and cardiac anomalies
To avoid strain-specific lethality in the knock-in mice expressing the Braf Q241R mutation, we first crossed the surviving PD0325901-treated Braf Q241R /+ B6 mice we had generated previ- (Fig. 2D) . In contrast, the skull widths of the Braf +/+ and Braf Q241R/+ mice were comparable, resulting in a significant increase in the width/length ratio (Fig. 2D ).
It has been reported that a few patients with CFC syndrome exhibit fast-growing or dystrophic nails, clinodactyly, crowded or overlapping toes and syndactly (18, 19 and Braf Q241R/+ (n = 11)]. **P < 0.001, ***P < 0.0001 versus Braf
The Braf +/+ and Braf Q241R/+ mice were placed in a conditioning chamber, and three tone-shock pairs were delivered at the indicated points. A tone was sounded for 30 s as the CS (bars) and a mild footshock was delivered for 2 s (arrows) at the end of the CS as the US (conditioning: top panel). Twenty-four hours later, the mice were placed back into the same conditioning chamber and the animals' freezing behavior was measured (context test: middle panel). Three to four hours later, the mice were placed into a distinct chamber for 6 min (cued test: bottom panel). Three minutes after starting the cued test, the tone (CS) was sounded for 3 min (n = 12), P = 0. mice showed an obvious defect in the contextual fear-conditioning test. In this experiment, an aversive mild footshock (unconditioned stimulus; US) was paired with an auditory conditioned stimulus (CS) within a novel environment. Twenty-four hours after the training, the Braf +/+ mice exhibited marked fear, freezing behavior, in response to re-presentation of the context (context test), suggesting that mice learned and remembered an association between the context and US (Fig. 2E) (Fig. 3A) . The pulsed-wave Doppler waveforms at the pulmonary valve in the Braf +/+ mice showed a laminar flow with normal outflow velocities (Fig. 3B) , whereas, in all Braf Q241R/+ mice, the ejection speed was higher than in the Braf +/+ mice, suggesting that these Braf Q241R/+ mice have pulmonary stenosis (Fig. 3B ). M-mode echocardiography to evaluate the heart function revealed that the left ventricular (LV) internal end-diastolic dimension (LVIDd), LV internal end-systolic dimension (LVIDs), LV diastolic posterior wall thickness (LVPWTd) and end-diastolic interventricular septum (IVSd) in the Braf +/+ and Braf Q241R/+ mice were comparable ( Fig. 3C ; Supplementary Material, Table S4 ). Likewise, the LV fractional shortening (LVFS) and ejection fraction (EF), an index of systolic function, in the Braf
and Braf Q241R/+ mice were comparable (Fig. 3D ). These data suggest that the Braf Q241R/+ mice have structural abnormalities, including ASDs and pulmonary stenosis, without obvious systolic and diastolic dysfunction.
Pulmonary valve stenosis was induced by thickened valve leaflets, without evidence of infundibular stenosis in the Braf Q241R/+ ICR embryos
To evaluate the development of the cardiac valves and heart structure, we performed histologic examination of the heart in Braf Q241R/+ embryos at E16.5. Four of seven Braf Q241R/+ embryos had thickened pulmonary valve leaflets compared with the Braf +/+ mice ( Fig. 4A and B) . Four of seven Braf Q241R/+ embryos had a dramatic increase in the density of the trabeculae (hypertrabeculation) (lower panel, Fig. 4A ), although mild hypertrabeculation was observed in two of eight Braf +/+ embryos (data not shown). Measurement of the thickness of cardiac valves revealed that the pulmonary and mitral valve leaflets were significantly In addition to the structural defects in the heart, including pulmonary valve stenosis and ASDs, patients with CFC syndrome frequently exhibit hypertrophic cardiomyopathy (5,6). Histologic analysis showed that the heart size in the 26-week-old Braf Q241R/+ mice was comparable with that in the Braf +/+ mice (Fig. 5A) . The HW to BW ratio was significantly higher in the Braf Q241R/+ mice than in the Braf +/+ mice (Fig. 5B) . However, there were no differences in cardiomyocyte size (Fig. 5C ) and number (data not shown) in the Braf +/+ and Braf Q241R/+ mice. The mRNA levels of the fetal cardiac genes Myh7 (mice) and MYH6 (human), which are reactivated in the heart tissues of mice and humans with hypertrophic cardiomyopathy (21, 22) , were similar in the Braf
and Braf Q241R/+ mice (data not shown). Likewise, there were no differences in the mRNA levels of several hypertrophic cardiomyopathy/heart failure markers, including Nppb and Atp2a2 (23,24) (data not shown). Sirius staining did not revealed fibrosis in the Braf +/+ and Braf Q241R/+ mice (Fig. 5D ). These observations suggested that the Braf Q241R/+ mice have a higher HW to BW ratio than the Braf +/+ mice, which is not associated with hypertrophic cardiomyopathy.
To further explore whether Braf Q241R/+ mice have cardiomyocyte damage, we examined the ultrastructure of the cardiomyocytes of the LV using transmission electron microscopy. Electron microscopy analysis indicated a normal sarcomeric structure and sarcoplasmic reticulum in the Braf +/+ and Braf Q241R/+ mice (Fig. 5E ).
However, the mitochondria from two of four Braf Q241R/+ mice were irregular in shape and heterogeneous in size ( Fig. 5E and F) . Half of the remaining mice had numerous granules in the mitochondria, an index of cell injury (Fig. 5F ). To investigate whether the mitochondrial function was altered in Braf Q241R/+ mice, western blotting analysis was performed using cell extracts derived from the hearts. The levels of the MFN1 and OPA1 mitochondrial fusion proteins, but not MFN2, were significantly higher in the Braf Q241R/+ mice than in the Braf +/+ mice (Fig. 5G) . In contrast, there were no differences in the levels of the DLP1 and FIS1 mitochondrial fission proteins (Fig. 5G ). These observations suggest that minor cell injury may occur in the myocardium of Braf Q241R/+ mice, although the histologic and mRNA expression analyses of the heart tissues did not identify any changes, such as a hypertrophic reaction or fibrosis.
The AKT pathway is down-regulated in Braf Q241R/+
ICR embryos and adult hearts
Finally, to investigate whether RAS/MAPK signaling was altered in the Braf Q241R/+ mice, we performed western blotting using cell lysates of whole mouse embryos and adult hearts. The levels of the phosphorylated ERK and p38 proteins in the Braf Q241R/+ whole embryos and adult hearts were similar to those of the Braf +/+ samples ( Fig. 6A and B) . In contrast, the levels of phosphorylated AKT (Ser473), which is not a direct target of BRAF, were significantly lower in the Braf Q241R/+ whole embryos (Fig. 6A) . The levels of phosphorylated AKT (Thr308) were significantly lower in both Braf Q241R/+ whole embryos and adult hearts than in the Braf +/+ samples ( Fig. 6A and B) .
Discussion
In the current study, we backcrossed Braf Q241R B6 mice (13) into the BALB/c (inbred) or ICR (outbred) genetic background. All Braf Q241R/+ BALB/c mice died between birth and 24 weeks. In contrast, 31% of the heterozygous Braf Q241R/+ ICR mice survived for over 74 weeks. Both the Braf Q241R/+ BALB/c and ICR mice displayed the characteristic features of CFC syndrome, including growth retardation, sparse and ruffled fur, an increase in the HW to BW ratio and ASDs. In addition, the Braf Q241R/+ ICR mice had additional CFC syndrome-related phenotypes, such as a hunched appearance, craniofacial dysmorphism, long and/or dystrophic nails, learning deficits and pulmonary valve stenosis. In contrast, extra digits and ovarian cysts observed in the Braf Q241R/+ ICR mice have not been reported in CFC syndrome patients. We conclude that the mice expressing Braf Q241R mutation will help elucidate the pathologic features of patients with CFC syndrome from birth to adulthood. The band intensity of each protein was quantified using ImageJ software, and then the phosphorylated proteins were normalized to the corresponding nonphosphorylated proteins. The data are shown as the mean ± SD [Braf +/+ (n = 6) and Braf Q241R/+ (n = 5)]. *P < 0.05 versus Braf +/+ (Student's t-test).
Two knock-in mice expressing Braf mutations have been reported: mice expressing the BRAF L597V mutation (BRAF L597V mice) and mice expressing a hypomorphic V600E allele (BRAF V600E mice) (25, 26) . The BRAF L597V mutation has been identified in three patients with Noonan syndrome/CFC syndrome (11, 27, 28) , whereas the V600E mutation has been identified in somatic cancers, but not in CFC syndrome. These mice have been shown to exhibit growth retardation, a reduced life span and craniofacial dysmorphism (25, 26) , which were observed in our Braf Q241R/+ ICR mice. BRAF V600E mice have been reported to exhibit seizures, one of the CFC syndrome phenotypes. In contrast, our Braf Q241R/+ ICR mice showed fur abnormalities, a hunched appearance (such as kyphosis) and long and/or dystrophic nails, which has not been reported in other mouse models. Most patients with CFC syndrome show neurologic abnormalities, including intellectual disability and a developmental delay with speech. Indeed, we have found, for the first time, that the Braf Q241R/+ ICR mice display learning deficits.
Three individuals with BRAF mutations have been reported to have developed acute lymphoblastic leukemia and non-Hodgkin's lymphoma (5, 12) . Lung adenoma and melanocytic hyperplasia have been observed in BRAF V600E mice, and benign tumors, including skin papillomas and intestinal polyps, have been observed in BRAF L597V mice (25, 26) . Our surviving Braf Q241R/+ ICR mice had not developed obvious benign and malignant tumors as of 1 year of age (data not shown), which is consistent with the fact that malignant tumors are rare in CFC syndrome. Collectively, these results suggest that our Braf Q241R/+ ICR mice will be useful for exploring the pathogenesis of the fur abnormalities, skeletal abnormalities, long and/or dystrophic nails and learning deficits in CFC syndrome. Heart defects are one of the most common features observed in individuals with CFC syndrome. Valvular pulmonary stenosis, hypertrophic cardiomyopathy, ASDs, VSDs and arrhythmia have been observed in 50, 38, 28, 11 and 20% of patients with CFC syndrome, respectively (6, 12) . Indeed, echocardiography of the 26-to 31-week-old Braf Q241R/+ ICR mice suggested pulmonary stenosis and ASDs. Histologic analysis of the heart showed that the Braf Q241R/+ ICR embryos had thickened pulmonary and mitral valve leaflets and hypertrabeculation, confirming the finding of pulmonary stenosis observed by echocardiography. ASDs were frequently observed in the neonatal Braf Q241R/+ BALB/c mice, suggesting that the Braf Q241R allele contributes to the development of congenital heart disease. In contrast, the surviving Braf Q241R/+ ICR mice did not develop hypertrophic cardiomyopathy, even at 1 year of age (data not shown), although an increase in the heart to BW ratio was observed in the Braf Q241R/+ ICR mice. BRAF L597V
and BRAF V600E mice have been found to exhibit cardiomegaly and hypertrophic cardiomyopathy (25, 26) . Congenital heart defects, such as pulmonary valve stenosis, ASDs and VSDs, have not been reported in these mice (25, 26) . These results suggest that the Q241R mutation, which is frequently identified in CFC syndrome, affects the development of the heart structure and valve leaflets. However, it is possible that the differences in the heart defects in these Braf mutant mice depend on multiple factors, such as the genetic background, environmental conditions and the type of Braf mutation. The genetic background influences the phenotype of genetically engineered mice. In mouse models of RASopathies, Araki et al. reported that approximately half of the knock-in mice (on a mixed 129S4/SvJae × C57BL/6J background) expressing the PTPN11 D61G mutation, which is associated with Noonan syndrome, survived for >3 weeks (29) . In contrast, almost all mice (∼97%) were dead within 3 weeks when these PTPN11 D61G mice were crossed with C57BL/6J mice. Furthermore, these mice on a BALB/c background were equally as viable as those on a 129S4/SvJae × C57BL/6J background. Urosevic et al. reported that survival was increased when knock-in mice expressing a hypomorphic BRAF V600E allele (on a mixed 129Sv/J × C57BL/6 background) were backcrossed onto an ICR background, but not onto a C57BL/6 background (26) . In our mouse model of CFC syndrome, the BALB/c or ICR genetic background ameliorated the embryonic lethality associated with the Braf Q241R B6 mice, despite the differences in the survival period after birth. However, the Braf Q241R/+ B6 mice exhibited embryonic/neonatal lethality, with edema, heart defects, lymphatic defects and craniofacial abnormalities (13) . These findings demonstrate that mice on the 129, BALB/c or ICR genetic backgrounds are more likely to have a survival advantage than those on a C57BL/6 background in mouse models of RASopathies, suggesting that there are strainspecific modifiers. It remains unknown why phosphorylated AKT (Ser473) and/or AKT (Thr308) expression were reduced in the Braf Q241R/+ ICR embryos and adult hearts. Interestingly, we have previously identified these phenomena in Braf Q241R/+ B6 embryo hearts (13), although they have not been found in other knock-in mouse models for RASopathies, including Noonan syndrome, Costello syndrome and Noonan syndrome with multiple lentigines. Constitutive MEK/ERK signaling activation in the heart is associated with cardiac hypertrophy (30) . Likewise, myocardialspecific transgenic mice expressing AKT have been shown to develop increased cardiomyocyte size and HW to BW ratios (31) . In the present study, the Braf Q241R/+ ICR mice exhibited an increase in the HW to BW ratio, whereas the expression of phosphorylated AKT (Thr308), but not phosphorylated ERK, was decreased. These results suggest that the decreased expression of phosphorylated AKT (Thr308) could represent a negative feedback mechanism for preventing hypertrophic cardiomyopathy. Recent studies have demonstrated that treatment with the MEK inhibitors PD184352 and PD0325901 or with a fibroblast growth factor receptor 1 (FGFR1) inhibitor, SU-5402, ameliorates the cell motility defects in zebrafish expressing CFC mutations during early embryogenesis (32, 33) . We have reported that prenatal treatment with PD0325901 or with a histone 3 demethylase inhibitor, GSK-J4 or NCDM-32b, rescued the embryonic and postnatal lethality in Braf Q241R/+ B6 mice (13) . Moreover, treatment with both PD0325901 and GSK-J4 further rescued the embryonic lethality compared with the Braf Q241R/+ B6 mice treated with PD0325901 or GSK-J4 alone (13) . In the present study, we used the ICR/CD-1 outbred mouse strain. Because this strain of outbred mice has genetic heterozygosity comparable with the differences in humans, these mice are commonly used for pharmacologic studies (34) (35) (36) . Thus, our new mouse model, the Braf Q241R/+ ICR mice, will be useful not only for elucidating the pathophysiology of the clinical features observed in CFC patients but also for evaluating the therapeutic effects of drugs and compounds on CFC syndrome.
Materials and Methods

Mice
The generation of Braf Q241R B6 mice has been previously described (13) . C57BL/6J, BALB/c and ICR mice were purchased from Charles River Laboratories Japan (Yokohama, Japan). The mice were maintained under a 12-h light/12-h dark cycle and fed a conventional laboratory diet, Labo MR Stock (Nihon Nosan Kogyo, Yokohama, Japan). Generation of Braf Q241R mice on a BALB/c or ICR 
X-ray CT scan
The mouse skulls were scanned using CT scans (Latheta LCT200; Hitachi Aloka Medical Ltd, Tokyo, Japan) and visualized with the VGStudio Max 2.0 software (Volume Graphics GmbH, Heidelberg, Germany). The craniofacial measurements were made according to The Jackson Laboratory standard protocols and procedures (http://craniofacial.jax.org/standard_protocols.html).
Behavioral tests
The behavioral tests were performed with male littermates. The open-field test, light-dark transition test, Y-maze test, and contextual and cued fear-conditioning tests were performed with equipment from O'Hara & Co. Ltd (Tokyo, Japan), essentially as previously described, with slight modifications (37, 38) . In these tests, the digital images of the mice were recorded with a CCD camera and were analyzed with ImageJ-OFC, ImageJ-LD1, Time For the light-dark transition test, the mice were allowed to move freely between the two equal-size chambers (21 × 21 × 25 cm), which were separated by a door. One chamber was illuminated at 390 lux, and the other chamber was dark (10 lux). At the start of the test, the mice were placed into the dark chamber, and their behavior was monitored for 10 min. The first latency to enter the light chamber, total number of transitions, time spent in each chamber and distance traveled were calculated by analyzing the images using the ImageJ-LD1 software. For the Y-maze test, the spontaneous alternation behavior was examined in an acrylic Y-shaped maze. This maze consists of three identical arms (length: 40 cm; high: 12 cm; width at bottom: 3 cm; width at top: 12 cm) converging at the center of a triangular area to form a symmetrical Y shape (120°of angular deviation from each other). A mouse was placed at the end of one arm and was allowed to freely explore the maze for 5 min. The sequence and total number of arm entries were recorded. The percent alternation is the number of triads containing entries into all three arms divided by the maximum possible number of alternations (the total number of arms entered minus 2) × 100. The data were analyzed automatically using the Time YM1 software. For the fear-conditioning test, the individual mice were placed into the conditioning chamber (10.5 × 10.5 × 10.5 cm, 200 lux, inside a sound-proof box), which had transparent acrylic walls and a stainless steel grid floor, and allowed to freely explore the apparatus for 88 s. An auditory CS (60 dB, 10 kHz) was sounded as the CS for 30 s through a speaker on the ceiling of the sound-proof box. At the end of the tone presentation, a scrambled electrical footshock (0.3 mA, 2 s) was delivered from the metal grid floor as the US. Two more tone-shock pairs were given at 88 s intervals (conditioning session). Twenty-four hours after the conditioning, the mice were placed back into the conditioning chamber for 5 min without the CS and US presentations (context test). At 3-5 h after the context text, the mice were placed into a distinct chamber with opaque white walls for 6 min (cued test). Three minutes after starting the test, the tone (CS) was sounded for 3 min. The images were captured at a rate of one frame per second. For each pair of successive frames, the area (pixels) within which the mouse moved was measured. When the area was below a certain threshold (100 pixels), the mouse was judged to be 'immobile'. The optimal threshold (number of pixels) for the definition of immobility was determined by adjustment based on human observation. The immobility was automatically determined from the images using the Time FZ1 software and expressed as a percentage of the immobility time in each 1 min period.
Western blotting
Whole mouse embryos and the LV myocardia of adult mice were lysed in lysis buffer [(10 m Tris-HCl, pH 8.0 and 1% sodium dodecyl sulfate (SDS)] containing phosphatase and protease inhibitor cocktails (P5726 and P8340, respectively; Sigma-Aldrich, St. Louis, MO). These lysates were centrifuged at 20 400g for 30 min at 15°C, and the protein concentration was determined by the Bradford method using the Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA), with bovine serum albumin as the standard. The lysates were subjected to SDS-polyacrylamide gel electrophoresis [4-20% Criterion TGX Precast Gels (Bio-Rad Laboratories)] and transferred to nitrocellulose membranes (Trans-Blot Turbo transfer pack; Bio-Rad Laboratories) using the Trans-Blot Turbo Transfer System (Bio-Rad Laboratories). Antibodies specific for the following proteins were used (with catalog numbers in parentheses): ERK1/2 (9102), phospho-ERK1/2 (9101), p38 (9212), phospho-p38 (4511), AKT (9272), phospho-AKT (on Ser473; 9018), phospho-AKT (on Thr308; 2965) and GAPDH (2118) from Cell Signaling (Danvers, MA); MFN1 (sc-50330) and FIS1 (sc-98900) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); DLP1 (611112) and OPA1 (612606) from BD Transduction Laboratories (San Jose, CA, USA); and MFN2 (M6319) from Sigma-Aldrich. All of the membranes were visualized using the Western Lightning ECL-Plus Kit (PerkinElmer, Waltham, MA). The band intensities were quantified using ImageJ software. The levels of the phosphorylated proteins were normalized to the non-phosphorylated proteins.
Histology and immunohistochemistry
The embryonic hearts were perfused with phosphate-buffered saline and 10% neutral-buffered formalin from the placenta. The embryonic, neonatal (at P5) and adult hearts were fixed in 10% neutral-buffered formalin, and the fixed hearts were embedded in paraffin. The embedded tissues were sectioned at 6 (embryonic hearts), 8 (neonatal hearts) or 3 μm (adult hearts). The sections were stained with hematoxylin and eosin (H&E) or picrosirius red. To determine the cross-sectional areas of the cardiomyocytes, the sections were stained with fluorescein isothiocyanate-labeled wheat germ agglutinin (FITC-WGA, L4895; Sigma-Aldrich) for 1 h at room temperature. The slides were mounted with the ProLong Gold antifade reagent with 4′, 6-diamidino-2-phenylindole. The cardiomyocytes with nuclei were quantitated using ImageJ software.
Echocardiography
Transthoracic echocardiography was performed on mice anesthetized with 4.0-1.0% isoflurane (150-200 ml/min) with a Nemio 35 ultrasound system (Toshiba) provided with a 12 MHz imaging transducer. The hemodynamics and LV systolic function were analyzed as previously described (39) . An index of systolic function was defined as the percentage of LVFS with echocardiographic measurements of LVIDd and LVIDs using the following standard equation: % LVFS = [(LVIDd-LVIDs)/LVIDd] × 100. Pulmonary valve disease (stenosis) or septal defects were assessed by the Doppler examination, as previously described (39) .
Electron microscopy
The left ventricle myocardia of the adult mice were dissected and fixed overnight with 2% paraformaldehyde and 2% in 0.1 M phosphate buffer (PB) ( pH 7.4) at 4°C. The fixed samples were then washed three times with 0.1 M PB for 30 min each, postfixed with 2% osmium tetroxide in 0.1 M PB for 2 h at 4°C and dehydrated in graded ethanol solutions. The samples were placed in a 70:30 mixture of propylene oxide and Quetol-812 resin (Nisshin EM, Tokyo, Japan) for 1 h, transferred to a fresh 100% resin and then polymerized at 60°C for 48 h. Ultra-thin sections (70 nm) were cut using an ultramicrotome (Ultracut UCT; Leica, Vienna, Austria) and stained with 2% uranyl acetate and a lead stain solution (Sigma-Aldrich). The stained sections were observed with a transmission electron microscope (JEM-1400Plus; JEOL, Tokyo, Japan).
Statistical analysis
All statistical analyses were performed using Prism software (ver. 6.01; GraphPad Software, Inc., San Diego, CA). The data were analyzed using Student's t-test for unpaired samples and the χ 2 test for the differences between the observed and expected distributions. The mouse survival was calculated using the Kaplan-Meier method and analyzed using the log-rank test. The differences were considered significant at a P-value of < 0.05.
